BioSpace News Archive

Samus Therapeutics, Inc. (“Samus” or the “Company”), a privately held, Boston -based, biopharmaceutical company developing epichaperome inhibitors to intervene in pathological processes and initiate the degradation of disease-associated proteins, today announced that Dick Bagley , President and Interim Chief Executive Officer,

CooperCompanies announced it will release first quarter 2020 financial results on Thursday, March 5, 2020, at 4:15 PM ET.

Halo Communications, a leading clinical communication and collaboration platform provider for health systems, announces the hiring of healthcare IT industry veteran, Kurt Hammond as Chief Growth Officer.

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 168,250 shares of Akebia’s common stock on January 31, 2020, as inducements material to each such employee’s entering into employment with Akebia.

Globe Life Inc. (NYSE: GL) reported today that for the quarter ended December 31, 2019, net income was $1.69 per diluted common share, compared with $1.45 per diluted common share for the year-ago quarter.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2019.

Globus Medical, Inc., a leading musculoskeletal solutions company announced Dr. Joshua S. Rovner became the first spine surgeon to implant HEDRON IA, a 3D printed integrated ALIF spacer that leverages anchors or screws for vertebral body fixation.

Kezar Life Sciences, Inc. announced the closing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share.

The 3M Board of Directors declared a dividend on the company’s common stock of $1.47 per share for the first quarter of 2020, an increase of 2 percent over the quarterly dividend paid in 2019.

MEDISCA Pharmaceutique Inc., a global leader of innovative products and services for the pharmaceutical compounding industry, is pleased to announce the issuance of United States Patent 10,420,705, covering an adapter for use in planetary mixers.